

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
31 October 2024 (31.10.2024)



(10) International Publication Number  
**WO 2024/227119 A3**

(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 47/54 (2017.01)  
A61K 47/50 (2017.01) A61K 31/33 (2006.01)  
A61K 47/51 (2017.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(21) International Application Number:

PCT/US2024/026709

(22) International Filing Date:

28 April 2024 (28.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/498,852 28 April 2023 (28.04.2023) US  
63/517,984 07 August 2023 (07.08.2023) US

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

02 January 2025 (02.01.2025)

(71) Applicant: **BIOHAVEN THERAPEUTICS LTD.**  
[US/GB]; Ritter House, P.O. Box 173, Road Town, Tortola,  
VG1110 (VG).

(72) Inventors: **DUBOWCHIK, Gene M.**; Biohaven Pharma-  
ceuticals, Inc., 215 Church Street, New Haven, Connecticut  
06510 (US). **KAZMIERSKI, Wieslaw**; Biohaven Pharma-  
ceuticals, Inc., 215 Church Street, New Haven, Connecticut  
06510 (US).

(74) Agent: **ZUEV, Dmitry**; Biohaven Pharmaceuticals, Inc.,  
215 Church Street, New Haven, Connecticut 06510 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PRO-  
TEINS

(57) Abstract: The present invention is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In certain embodiments, the (CPBM) is a moiety which binds to Immunoglobulin G. In certain embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte.

WO 2024/227119 A3